Lopinavir-d8 – 1 mg

Brand:
Cayman
CAS:
1322625-54-6
Storage:
-20
UN-No:
Non-Hazardous - /

Lopinavir-d8 is intended for use as an internal standard for the quantification of lopinavir (Item No. 13854) by GC- or LC-MS. Lopinavir is a potent HIV-1 protease inhibitor (Ki = 1.3 pM for wild-type enzyme).{24199} It inhibits the replication of clinical isolates of HIV-1 (EC50s = 5-52 nM). Lopinavir reduces the infectious virus yield and viral RNA copy numbers in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50s = 26.63 and 26.10 µM, respectively).{53655} It reduces lung and kidney viral load, bronchointerstitial pneumonia, and pulmonary inflammatory cell infiltration in a marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered in combination with ritonavir (Item No. 13872).{53656}  

 

Available on backorder

SKU: 25284 - 1 mg Category:

Description

An internal standard for the quantification of lopinavir by GC- or LC-MS


Formal name: rel-N-[(1R,3R,4R)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-[1-(methyl-d3)ethyl-1,2,2,2-d4]-2-oxo-1(2H)-pyrimidineacetamide-α-d

Synonyms: 

Molecular weight: 636.9

CAS: 1322625-54-6

Purity: ≥99% deuterated forms (d1-d8)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Antivirals|Protease Inhibitors||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Immunology & Inflammation|Pulmonary Diseases|COVID-19||Research Area|Immunology & Inflammation|Pulmonary Diseases|SARS||Research Area|Infectious Disease|Viral Diseases|Coronaviruses||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS